{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T02:32:29Z","timestamp":1772937149734,"version":"3.50.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["T32NS105602"],"award-info":[{"award-number":["T32NS105602"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1TR002375"],"award-info":[{"award-number":["TL1TR002375"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1TR002375"],"award-info":[{"award-number":["TL1TR002375"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001395","name":"Wisconsin Alumni Research Foundation","doi-asserted-by":"publisher","award":["MSN251969"],"award-info":[{"award-number":["MSN251969"]}],"id":[{"id":"10.13039\/100001395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001395","name":"Wisconsin Alumni Research Foundation","doi-asserted-by":"publisher","award":["MSN251969"],"award-info":[{"award-number":["MSN251969"]}],"id":[{"id":"10.13039\/100001395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001395","name":"Wisconsin Alumni Research Foundation","doi-asserted-by":"publisher","award":["MSN251969"],"award-info":[{"award-number":["MSN251969"]}],"id":[{"id":"10.13039\/100001395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001395","name":"Wisconsin Alumni Research Foundation","doi-asserted-by":"publisher","award":["MSN251969"],"award-info":[{"award-number":["MSN251969"]}],"id":[{"id":"10.13039\/100001395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12613-3","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T20:45:49Z","timestamp":1753130749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quantitative and qualitative influences of spiritual connection and natural imagery on perception of art in clinical psychedelic dosing settings"],"prefix":"10.1038","volume":"15","author":[{"given":"Suhjung Janet","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Epland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah","family":"Kaitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olayinka","family":"Shiyanbola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cody J.","family":"Wenthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"12613_CR1","doi-asserted-by":"crossref","unstructured":"Hughes, M. E. & Garcia-Romeu, A. Ethnoracial inclusion in clinical trials of psychedelics: a systematic review. eClinicalMedicine 74, (2024).","DOI":"10.1016\/j.eclinm.2024.102711"},{"key":"12613_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12888-018-1824-6","volume":"18","author":"TI Michaels","year":"2018","unstructured":"Michaels, T. I., Purdon, J., Collins, A. & Williams, M. T. Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. BMC Psychiatry. 18, 245 (2018).","journal-title":"BMC Psychiatry"},{"key":"12613_CR3","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s11845-021-02668-2","volume":"1971-191","author":"K Corrigan","year":"2022","unstructured":"Corrigan, K. et al. Psychedelic perceptions: mental health service user attitudes to psilocybin therapy. Ir. J. Med. Sci. 1971-191, 1385\u20131397 (2022).","journal-title":"Ir. J. Med. Sci."},{"key":"12613_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1177\/13634615221100385","volume":"59","author":"I Hartogsohn","year":"2022","unstructured":"Hartogsohn, I. Modalities of the psychedelic experience: microclimates of set and setting in hallucinogen research and culture. Transcult Psychiatry. 59, 579\u2013591 (2022).","journal-title":"Transcult Psychiatry"},{"key":"12613_CR5","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/02698811231182602","volume":"37","author":"C Pronovost-Morgan","year":"2023","unstructured":"Pronovost-Morgan, C., Hartogsohn, I. & Ramaekers, J. G. Harnessing placebo: lessons from psychedelic science. J. Psychopharmacol. (Oxf). 37, 866\u2013875 (2023).","journal-title":"J. Psychopharmacol. (Oxf)"},{"key":"12613_CR6","doi-asserted-by":"publisher","first-page":"205032451668332","DOI":"10.1177\/2050324516683325","volume":"3","author":"I Hartogsohn","year":"2017","unstructured":"Hartogsohn, I. Constructing drug effects: A history of set and setting. Drug Sci. Policy Law. 3, 2050324516683325 (2017).","journal-title":"Drug Sci. Policy Law"},{"key":"12613_CR7","doi-asserted-by":"crossref","unstructured":"Barrett, F. S., Robbins, H., Smooke, D., Brown, J. L. & Griffiths, R. R. Qualitative and quantitative features of music reported to support peak mystical experiences during psychedelic therapy sessions. Front. Psychol. 8, 1238 (2017).","DOI":"10.3389\/fpsyg.2017.01238"},{"key":"12613_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.drugpo.2017.07.017","volume":"49","author":"F B\u00f8hling","year":"2017","unstructured":"B\u00f8hling, F. Psychedelic pleasures: an affective Understanding of the joys of tripping. Int. J. Drug Policy. 49, 133\u2013143 (2017).","journal-title":"Int. J. Drug Policy"},{"key":"12613_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/7854_2021_298","volume-title":"Disruptive Psychopharmacology","author":"TL Golden","year":"2022","unstructured":"Golden, T. L. et al. Effects of setting on psychedelic experiences, therapies, and outcomes: A rapid scoping review of the literature. In Disruptive Psychopharmacology (eds Barrett, F. S., Preller, K. H. et al.) 35\u201370 (Springer International Publishing, 2022). https:\/\/doi.org\/10.1007\/7854_2021_298."},{"key":"12613_CR10","doi-asserted-by":"crossref","unstructured":"Kettner, H. et al. Psychedelic communitas: intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness. Front. Pharmacol. 12, 623985 (2021).","DOI":"10.3389\/fphar.2021.623985"},{"key":"12613_CR11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1021\/acsptsci.0c00187","volume":"4","author":"JC Strickland","year":"2021","unstructured":"Strickland, J. C., Garcia-Romeu, A. & Johnson, M. W. Set and setting: A randomized study of different musical genres in supporting psychedelic therapy. ACS Pharmacol. Transl Sci. 4, 472\u2013478 (2021).","journal-title":"ACS Pharmacol. Transl Sci."},{"key":"12613_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/09540261.2018.1474185","volume":"30","author":"PS Hendricks","year":"2018","unstructured":"Hendricks, P. S. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. Int. Rev. Psychiatry. 30, 331\u2013342 (2018).","journal-title":"Int. Rev. Psychiatry"},{"key":"12613_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0269881114568040","volume":"29","author":"T Maji\u0107","year":"2015","unstructured":"Maji\u0107, T., Schmidt, T. T. & Gallinat, J. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J. Psychopharmacol. (Oxf). 29, 241\u2013253 (2015).","journal-title":"J. Psychopharmacol. (Oxf)"},{"key":"12613_CR14","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2021","unstructured":"Yaden, D. B. & Griffiths, R. R. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol. Transl Sci. 4, 568\u2013572 (2021).","journal-title":"ACS Pharmacol. Transl Sci."},{"key":"12613_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson, M., Richards, W. & Griffiths, R. Human hallucinogen research: guidelines for safety. J. Psychopharmacol. (Oxf). 22, 603\u2013620 (2008).","journal-title":"J. Psychopharmacol. (Oxf)"},{"key":"12613_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1089\/psymed.2024.0003","volume":"2","author":"SG Gloeckler","year":"2024","unstructured":"Gloeckler, S. G., Lehmann, A., de la Salle, S., Greenway, K. T. & Lucas, P. Preferences and attitudes toward music in nonclinical uses of psychedelics. Psychedelic Med. 2, 201\u2013209 (2024).","journal-title":"Psychedelic Med."},{"key":"12613_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1089\/psymed.2023.0058","volume":"2","author":"AA Efthimiou","year":"2024","unstructured":"Efthimiou, A. A., Cardinale, A. M. & Kepa, A. The role of music in Psychedelic-Assisted therapy: A comparative analysis of neuroscientific research, Indigenous entheogenic ritual, and contemporary care models. Psychedelic Med. 2, 221\u2013233 (2024).","journal-title":"Psychedelic Med."},{"key":"12613_CR18","doi-asserted-by":"publisher","unstructured":"Patch, K. & Smith, W. R. What are set and setting: reducing vagueness to improve research and clinical practice. J. Psychopharmacol. (Oxf). 02698811251337372 https:\/\/doi.org\/10.1177\/02698811251337372 (2025).","DOI":"10.1177\/02698811251337372"},{"key":"12613_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/psymed.2024.0019","volume":"3","author":"DB Yaden","year":"2025","unstructured":"Yaden, D. B. et al. A Field-Wide review and analysis of study materials used in psilocybin trials: assessment of two decades of research. Psychedelic Med. 3, 1\u201318 (2025).","journal-title":"Psychedelic Med."},{"key":"12613_CR20","doi-asserted-by":"publisher","unstructured":"Pronovost-Morgan, C., Greenway, K. T. & Roseman, L. An international Delphi consensus for reporting of setting in psychedelic clinical trials. Nat. Med. 1\u201310. https:\/\/doi.org\/10.1038\/s41591-025-03685-9 (2025).","DOI":"10.1038\/s41591-025-03685-9"},{"key":"12613_CR21","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.3390\/ijerph16245147","volume":"16","author":"H Kettner","year":"2019","unstructured":"Kettner, H., Gandy, S., Haijen, E. C. H. M. & Carhart-Harris, R. L. From egoism to ecoism: psychedelics increase nature relatedness in a State-Mediated and Context-Dependent manner. Int. J. Environ. Res. Public. Health. 16, 5147 (2019).","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"12613_CR22","doi-asserted-by":"publisher","first-page":"10195","DOI":"10.1038\/s41598-024-60890-1","volume":"14","author":"DK Sj\u00f6str\u00f6m","year":"2024","unstructured":"Sj\u00f6str\u00f6m, D. K., Claesdotter-Knutsson, E. & Kajonius, P. J. Personality traits explain the relationship between psychedelic use and less depression in a comparative study. Sci. Rep. 14, 10195 (2024).","journal-title":"Sci. Rep."},{"key":"12613_CR23","doi-asserted-by":"publisher","unstructured":"Szigeti, B. et al. Assessing expectancy and suggestibility in a trial of Escitalopram v. psilocybin for depression. Psychol. Med. 1\u20138. https:\/\/doi.org\/10.1017\/S0033291723003653 (2024).","DOI":"10.1017\/S0033291723003653"},{"key":"12613_CR24","doi-asserted-by":"publisher","first-page":"22166","DOI":"10.1038\/s41598-021-01209-2","volume":"11","author":"C Timmermann","year":"2021","unstructured":"Timmermann, C. et al. Psychedelics alter metaphysical beliefs. Sci. Rep. 11, 22166 (2021).","journal-title":"Sci. Rep."},{"key":"12613_CR25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1017\/S0033291723001514","volume":"54","author":"B Weiss","year":"2024","unstructured":"Weiss, B. et al. Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. Psychol. Med. 54, 178\u2013192 (2024).","journal-title":"Psychol. Med."},{"key":"12613_CR26","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1037\/a0033161","volume":"60","author":"C Fl\u00fcckiger","year":"2013","unstructured":"Fl\u00fcckiger, C. et al. Substance use disorders and racial\/ethnic minorities matter: A meta-analytic examination of the relation between alliance and outcome. J. Couns. Psychol. 60, 610\u2013616 (2013).","journal-title":"J. Couns. Psychol."},{"key":"12613_CR27","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1176\/ps.2009.60.10.1336","volume":"60","author":"RS Shim","year":"2009","unstructured":"Shim, R. S., Compton, M. T., Rust, G., Druss, B. G. & Kaslow, N. J. Race-Ethnicity as a predictor of attitudes toward mental health treatment seeking. Psychiatr Serv. 60, 1336\u20131341 (2009).","journal-title":"Psychiatr Serv."},{"key":"12613_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1037\/14801-001","volume-title":"Addressing Cultural Complexities in Practice: Assessment, Diagnosis, and Therapy","author":"PA Hays","year":"2016","unstructured":"Hays, P. A. The new reality: diversity and complexity. In Addressing Cultural Complexities in Practice: Assessment, Diagnosis, and Therapy 3rd edn 3\u201318 (American Psychological Association, 2016). https:\/\/doi.org\/10.1037\/14801-001.","edition":"3"},{"key":"12613_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1556\/2054.2019.022","volume":"4","author":"L Neitzke-Spruill","year":"2019","unstructured":"Neitzke-Spruill, L. Race as a component of set and setting: how experiences of race can influence psychedelic experiences. J. Psychedelic Stud. 4, 51\u201360 (2019).","journal-title":"J. Psychedelic Stud."},{"key":"12613_CR30","doi-asserted-by":"publisher","first-page":"774736","DOI":"10.3389\/fpsyt.2021.774736","volume":"12","author":"DT Smith","year":"2022","unstructured":"Smith, D. T., Faber, S. C., Buchanan, N. T., Foster, D. & Green, L. The need for Psychedelic-Assisted therapy in the black community and the burdens of its provision. Front. Psychiatry. 12, 774736 (2022).","journal-title":"Front. Psychiatry"},{"key":"12613_CR31","doi-asserted-by":"publisher","unstructured":"Williams, M. T. & Labate, B. C. Diversity, equity, and access in psychedelic medicine. (2020). https:\/\/doi.org\/10.1556\/2054.2019.032","DOI":"10.1556\/2054.2019.032"},{"key":"12613_CR32","doi-asserted-by":"publisher","first-page":"16976","DOI":"10.1038\/s41598-022-18645-3","volume":"12","author":"GM Jones","year":"2022","unstructured":"Jones, G. M. & Nock, M. K. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality. Sci. Rep. 12, 16976 (2022).","journal-title":"Sci. Rep."},{"key":"12613_CR33","doi-asserted-by":"publisher","first-page":"205032452311846","DOI":"10.1177\/20503245231184638","volume":"9","author":"SM Vi\u00f1a","year":"2023","unstructured":"Vi\u00f1a, S. M. & Stephens, A. L. Minorities\u2019 diminished psychedelic returns. Drug Sci. Policy Law. 9, 20503245231184638 (2023).","journal-title":"Drug Sci. Policy Law"},{"key":"12613_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2024.2425021","volume":"0","author":"SM Vi\u00f1a","year":"2024","unstructured":"Vi\u00f1a, S. M. & Religion Psychedelics, risky behavior, and violence. J. Psychoact. Drugs. 0, 1\u201312 (2024).","journal-title":"J. Psychoact. Drugs"},{"key":"12613_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/0735648X.2009.9721270","volume":"32","author":"O Mitchell","year":"2009","unstructured":"Mitchell, O. Is the war on drugs Racially biased?? J. Crime. Justice. 32, 49\u201375 (2009).","journal-title":"J. Crime. Justice"},{"key":"12613_CR36","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","volume":"56","author":"RT Brown","year":"2017","unstructured":"Brown, R. T. et al. Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clin. Pharmacokinet. 56, 1543\u20131554 (2017).","journal-title":"Clin. Pharmacokinet."},{"key":"12613_CR37","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1177\/0269881118780713","volume":"32","author":"CR Nicholas","year":"2018","unstructured":"Nicholas, C. R. et al. High dose psilocybin is associated with positive subjective effects in healthy volunteers. J. Psychopharmacol. (Oxf). 32, 770\u2013778 (2018).","journal-title":"J. Psychopharmacol. (Oxf)"},{"key":"12613_CR38","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025\u20131033 (2021).","journal-title":"Nat. Med."},{"key":"12613_CR39","doi-asserted-by":"publisher","first-page":"109356","DOI":"10.1016\/j.drugalcdep.2022.109356","volume":"233","author":"CR Nicholas","year":"2022","unstructured":"Nicholas, C. R. et al. The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug Alcohol Depend. 233, 109356 (2022).","journal-title":"Drug Alcohol Depend."},{"key":"12613_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-024-03059-8","volume":"14","author":"CR Nicholas","year":"2024","unstructured":"Nicholas, C. R. et al. Co-administration of Midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience. Transl Psychiatry. 14, 1\u201311 (2024).","journal-title":"Transl Psychiatry"},{"key":"12613_CR41","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"JM Mitchell","year":"2023","unstructured":"Mitchell, J. M. et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat. Med. 29, 2473\u20132480 (2023).","journal-title":"Nat. Med."},{"key":"12613_CR42","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison, C. L. et al. Single-Dose psilocybin treatment for major depressive disorder: A randomized clinical trial. JAMA 330, 843\u2013853 (2023).","journal-title":"JAMA"},{"key":"12613_CR43","doi-asserted-by":"crossref","unstructured":"Brett, J. et al. Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. Front. Psychiatry 14, 1123424 (2023).","DOI":"10.3389\/fpsyt.2023.1123424"},{"key":"12613_CR44","doi-asserted-by":"crossref","unstructured":"Nicholas, C. R. et al. Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings. Psychedelic Med. 1, 253\u2013261 (2023).","DOI":"10.1089\/psymed.2023.0012"},{"key":"12613_CR45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1037\/1082-989X.8.2.129","volume":"8","author":"R Azen","year":"2003","unstructured":"Azen, R. & Budescu, D. V. The dominance analysis approach for comparing predictors in multiple regression. Psychol. Methods. 8, 129\u2013148 (2003).","journal-title":"Psychol. Methods"},{"key":"12613_CR46","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh, H. F. & Shannon, S. E. Three approaches to qualitative content analysis. Qual. Health Res. 15, 1277\u20131288 (2005).","journal-title":"Qual. Health Res."},{"key":"12613_CR47","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong, A., Sainsbury, P. & Craig, J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int. J. Qual. Health Care. 19, 349\u2013357 (2007).","journal-title":"Int. J. Qual. Health Care"},{"key":"12613_CR48","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2023.0044","author":"RR Griffiths","year":"2025","unstructured":"Griffiths, R. R. et al. Effects of psilocybin on religious and spiritual attitudes and behaviors in clergy from various major world religions. Psychedelic Med. https:\/\/doi.org\/10.1089\/psymed.2023.0044 (2025).","journal-title":"Psychedelic Med."},{"key":"12613_CR49","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/02791072.2018.1494869","volume":"50","author":"L Neitzke-Spruill","year":"2018","unstructured":"Neitzke-Spruill, L., Glasser, C. A. & Gratuitous Grace The influence of religious set and intent on the psychedelic experience. J. Psychoact. Drugs. 50, 314\u2013321 (2018).","journal-title":"J. Psychoact. Drugs"},{"key":"12613_CR50","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300","volume":"22","author":"R Griffiths","year":"2008","unstructured":"Griffiths, R., Richards, W., Johnson, M., McCann, U. & Jesse, R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J. Psychopharmacol. (Oxf). 22, 621\u2013632 (2008).","journal-title":"J. Psychopharmacol. (Oxf)"},{"key":"12613_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0269881117731279","volume":"32","author":"RR Griffiths","year":"2018","unstructured":"Griffiths, R. R. et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J. Psychopharmacol. (Oxf). 32, 49\u201369 (2018).","journal-title":"J. Psychopharmacol. (Oxf)"},{"key":"12613_CR52","unstructured":"Pahnke, W. N. Drugs and mysticism: An analysis of the relationship between psychedelic drugs and the mystical consciousness: A thesisHarvard University,. (1963)."},{"key":"12613_CR53","unstructured":"Pahnke, W. N. LSD and religious experience.  In LSD, man and society (eds DeBold, R. & Leaf, R.) 60\u201385 (Wesleyan University Press, Middletown, CT, 1967)."},{"key":"12613_CR54","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jama.2022.11086","volume":"328","author":"TA Balboni","year":"2022","unstructured":"Balboni, T. A. et al. Spirituality in serious illness and health. JAMA 328, 184\u2013197 (2022).","journal-title":"JAMA"},{"key":"12613_CR55","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1377\/hlthaff.2023.01643","volume":"43","author":"KNG Long","year":"2024","unstructured":"Long, K. N. G. et al. Spirituality as A determinant of health: emerging policies, practices, and systems. Health Aff (Millwood). 43, 783\u2013790 (2024).","journal-title":"Health Aff (Millwood)"},{"key":"12613_CR56","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/aje\/kwz204","volume":"189","author":"I Kawachi","year":"2020","unstructured":"Kawachi, I. Invited commentary: religion as a social determinant of health. Am. J. Epidemiol. 189, 1461\u20131463 (2020).","journal-title":"Am. J. Epidemiol."},{"key":"12613_CR57","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s44220-025-00417-3","volume":"3","author":"DH Grossman","year":"2025","unstructured":"Grossman, D. H. et al. A systematic review of income and education reporting in psychedelic clinical trials. Nat. Ment Health. 3, 567\u2013574 (2025).","journal-title":"Nat. Ment Health"},{"key":"12613_CR58","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1177\/0269881117714049","volume":"31","author":"M Forstmann","year":"2017","unstructured":"Forstmann, M. & Sagioglou, C. Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness. J. Psychopharmacol. (Oxf). 31, 975\u2013988 (2017).","journal-title":"J. Psychopharmacol. (Oxf)"},{"key":"12613_CR59","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1177\/0269881117748902","volume":"32","author":"T Lyons","year":"2018","unstructured":"Lyons, T. & Carhart-Harris, R. L. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. J. Psychopharmacol. (Oxf). 32, 811\u2013819 (2018).","journal-title":"J. Psychopharmacol. (Oxf)"},{"key":"12613_CR60","doi-asserted-by":"crossref","unstructured":"Haijen, E. C. H. M. et al. Predicting responses to psychedelics: A prospective study. Front. Pharmacol. 9, 897 (2018).","DOI":"10.3389\/fphar.2018.00897"},{"key":"12613_CR61","unstructured":"Wilson, E. O. Biophilia and the conservation ethic. In Evolutionary Perspectives on Environmental Problems 1st edn (eds Penn, D. J. & Mysterud, I.) (Routledge, 2007)."},{"key":"12613_CR62","doi-asserted-by":"crossref","unstructured":"Song, J., Kwak, Y. & Kim, C. Y. Familiarity and novelty in aesthetic preference: the effects of the properties of the artwork and the beholder. Front. Psychol. 12, 694927 (2021).","DOI":"10.3389\/fpsyg.2021.694927"},{"key":"12613_CR63","doi-asserted-by":"publisher","first-page":"750245","DOI":"10.3389\/fpsyg.2022.750245","volume":"13","author":"JS Gaekwad","year":"2022","unstructured":"Gaekwad, J. S., Moslehian, S., Ro\u00f6s, A., Walker, A. & P. B. & A Meta-Analysis of emotional evidence for the biophilia hypothesis and implications for biophilic design. Front. Psychol. 13, 750245 (2022).","journal-title":"Front. Psychol."},{"key":"12613_CR64","doi-asserted-by":"publisher","first-page":"101921","DOI":"10.1016\/j.cpr.2020.101921","volume":"82","author":"AL Baier","year":"2020","unstructured":"Baier, A. L., Kline, A. C. & Feeny, N. C. Therapeutic alliance as a mediator of change: A systematic review and evaluation of research. Clin. Psychol. Rev. 82, 101921 (2020).","journal-title":"Clin. Psychol. Rev."},{"key":"12613_CR65","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/0021-9681(87)90080-4","volume":"40","author":"GH Guyatt","year":"1987","unstructured":"Guyatt, G. H., Townsend, M., Berman, L. B. & Keller, J. L. A comparison of likert and visual analogue scales for measuring change in function. J. Chronic Dis. 40, 1129\u20131133 (1987).","journal-title":"J. Chronic Dis."},{"key":"12613_CR66","first-page":"178","volume":"8","author":"D Hasson","year":"2005","unstructured":"Hasson, D. & Arnetz, B. B. Validation and findings comparing VAS vs. Likert scales for psychosocial measurements. Int. Electron. J. Health Educ. 8, 178\u2013192 (2005).","journal-title":"Int. Electron. J. Health Educ."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12613-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12613-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12613-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T19:12:15Z","timestamp":1757272335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12613-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12613"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12613-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CJW discloses the receipt of funding from Psilera Inc. and free research materials from the Usona Institute to study the application of psychedelics as treatments for psychiatric disorders \u2013 these groups had no direct influence over the contents of this study or manuscript. All other authors have no disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26500"}}